The aim of the project is to develop, evaluate and translate into patients, new and highly innovative molecular imaging methods with positron emission tomography (PET), 13C-hyperpolarized magnetic resonance spectroscopic imaging (MRSI) and optical imaging demonstrating the aggressiveness and metastatic potential of cancers. Also, β and α emitting therapy will be developed and used together with imaging as theranostic pairs. Our methods will be used for better cancer imaging and tailoring therapy. The common target of our new technologies is the urokinase-type plasminogen activator receptor (uPAR), which is part of a proteolytic system and one of the most well-established markers of cancer aggressiveness. Accordingly, our methods are not merely diagnostic but also prognostic which will be used for selecting and tailoring cancer therapy for better outcome.